1.98Open2.90Pre Close5 Volume71 Open Interest22.50Strike Price990.00Turnover130.06%IV5.38%PremiumJan 17, 2025Expiry Date0.73Intrinsic Value100Multiplier12DDays to Expiry1.25Extrinsic Value100Contract SizeAmericanOptions Type0.6023Delta0.0687Gamma8.93Leverage Ratio-0.0891Theta0.0039Rho5.38Eff Leverage0.0166Vega
Neurogene Stock Discussion
This Will continue to drive downward. And after you finally sell your position for a loss, they will buy back. Follow the money
📊⚡️📊
NEWS
Neurogene Announces Upcoming Presentation of Safety Data from Phase 1/2 Trial of NGN-401 Gene Therapy for Rett Syndrome at ASGCT Meeting
NEW YORK--(BUSINESS WIRE)-- Neurogene Inc. (Nasdaq: NGNE), a clinical-stage company founded to bring life-changing genetic medicines to patients and families affected by rare neurological diseases, today announced that initial safety and tolerability data from its ongoing Phase 1/2 gene therapy clinical trial for Rett syndrome will be ...
No comment yet